An all-Yale team of researchers successfully treated a patient with disfiguring sarcoidosis, a disease that can affect multiple organs, with a drug approved for rheumatoid arthritis. Successful treatment of two other patients with similarly severe disease suggests an effective treatment for an incurable, sometimes life-threatening illness is within reach.

The research was published in the New England Journal of Medicine.

While some patients with sarcoidosis recover without treatment, others suffer damage to the lungs, heart, lymph nodes, and other organs. Current treatments, including steroids, are not reliably effective for the skin and can cause serious side effects.

Based on clues gleaned from prior studies, the Yale team decided to try an arthritis medication, tofacitinib. The drug, a Jak inhibitor, blocks a pathway known as Jak-STAT. The lead author Brett King, M.D., has pioneered the use of Jak inhibitors to treat other intractable skin diseases, including vitiligo, alopecia areata, and eczema.

For several months, a 48-year-old female patient was treated with the drug, a twice-daily pill. The researchers observed that her skin lesions nearly disappeared. They also performed RNA sequencing on biopsied skin from the patient before and during treatment. “Before treatment, we were able to show that the Jak-STAT pathway is activated,” King said. “During treatment, not only does her skin disease go away, but there is no activation of the pathway.”

“We plan to evaluate the activation of the Jak-STAT pathway in the lung fluid and blood of over 200 patients with pulmonary and multiorgan sarcoidosis,“ said co-author Nkiruka Emeagwali. These are big steps toward understanding a disease that has been a mystery for years, the researchers said.

The findings are being tested further by the Yale team in a clinical trial. If confirmed, they could represent a breakthrough for sarcoidosis patients, King noted.

“A frequently awful disease, which to date has no reliably effective therapy, may now be targeted with Jak inhibitors,” he said. “We have a relatively safe medicine that works.”

Other Yale authors are William Damsky, Durga Thakral, and Anjela Galan.

This work was funded in part by the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research, the National Institutes of Health, and The Dermatology Foundation.

Dr. King is a consultant to and a clinical trials investigator for Pfizer, the maker of tofacitinib.